Essential multimeric enzymes in kinetoplastid parasites: A host of potentially druggable protein-protein interactions

Parasitic diseases caused by kinetoplastid parasites of the genera Trypanosoma and Leishmania are an urgent public health crisis in the developing world. These closely related species possess a number of multimeric enzymes in highly conserved pathways involved in vital functions, such as redox homeostasis and nucleotide synthesis. Computational alanine scanning of these protein-protein interfaces has revealed a host of potentially ligandable sites on several established and emerging anti-parasitic drug targets. Analysis of interfaces with multiple clustered hotspots has suggested several potentially inhibitable protein-protein interactions that may have been overlooked by previous large-scale analyses focusing solely on secondary structure. These protein-protein interactions provide a promising lead for the development of new peptide and macrocycle inhibitors of these enzymes.

• Publication year

  2017

• Venue

  PLoS Neglected Tropical Diseases

• Publication date

  2017-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1371/journal.pntd.0005720PMID 28662026PMCID 5507555
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Identifying Loop-Mediated Protein-Protein Interactions Using LoopFinder.

  2017cited by this paper
• Disclosing the essentiality of ribose-5-phosphate isomerase B in Trypanosomatids

  2016cited by this paper
• Mutational and Structural Analysis of Conserved Residues in Ribose-5-Phosphate Isomerase B from Leishmania donovani: Role in Substrate Recognition and Conformational Stability

  2016cited by this paper
• Approaches for Designing new Potent Inhibitors of Farnesyl Pyrophosphate Synthase

  2016cited by this paper
• Peptiderive server: derive peptide inhibitors from protein–protein interactions

  2016cited by this paper
• Structure-based discovery of the first non-covalent inhibitors of Leishmania major tryparedoxin peroxidase by high throughput docking

  2015cited by this paper
• Combined covalent-electrostatic model of hydrogen bonding improves structure prediction with Rosetta.

  2015cited by this paper
• Cyclic and Macrocyclic Peptides as Chemical Tools To Recognise Protein Surfaces and Probe Protein–Protein Interactions

  2015cited by this paper
• Global , regional , and national age – sex specifi c all-cause and cause-specifi c mortality for 240 causes of death , 1990 – 2013 : a systematic analysis for the Global Burden of Disease Study 2013

  2015cited by this paper
• In Vitro and In Vivo Investigation of the Inhibition of Trypanosoma brucei Cell Growth by Lipophilic Bisphosphonates

  2015cited by this paper
• Ribose 5-Phosphate Isomerase B Knockdown Compromises Trypanosoma brucei Bloodstream Form Infectivity

  2015cited by this paper
• Comparison of hydrocarbon-and lactam-bridged cyclic peptides as dimerization inhibitors of Leishmania infantum trypanothione reductase

  2015cited by this paper
• Farnesyl diphosphate synthase inhibitors with unique ligand-binding geometries.

  2015cited by this paper
• Mass Administration of Ivermectin for the Elimination of Onchocerciasis Significantly Reduced and Maintained Low the Prevalence of Strongyloides stercoralis in Esmeraldas, Ecuador

  2015cited by this paper
• Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

  2015cited by this paper
• Comprehensive Analysis of Loops at Protein-Protein Interfaces for Macrocycle Design

  2014cited by this paper
• Small-molecule inhibitors of protein-protein interactions: progressing toward the reality.

  2014cited by this paper
• Structure-Based Design and Synthesis of Antiparasitic Pyrrolopyrimidines Targeting Pteridine Reductase 1

  2014cited by this paper
• Genetic Validation of Trypanosoma brucei Glutathione Synthetase as an Essential Enzyme

  2014cited by this paper
• Structure of tyrosine aminotransferase from Leishmania infantum

  2014cited by this paper
• Repurposing human Aurora kinase inhibitors as leads for anti-protozoan drug discovery.

  2014cited by this paper
• In silico molecular modeling and docking studies on the leishmanial tryparedoxin peroxidase

  2014cited by this paper
• Design of an interface peptide as new inhibitor of human glucose-6-phosphate dehydrogenase.

  2014cited by this paper
• Probing the Dimerization Interface of Leishmania infantum Trypanothione Reductase with Site‐Directed Mutagenesis and Short Peptides

  2013cited by this paper
• HippDB: a database of readily targeted helical protein-protein interactions

  2013cited by this paper
• Reversible Cysteine Protease Inhibitors Show Promise for a Chagas Disease Cure

  2013cited by this paper
• Trypanosomatidae diseases: from the current therapy to the efficacious role of trypanothione reductase in drug discovery.

  2013cited by this paper
• Inhibition of Trypanothione Synthetase as a Therapeutic Concept

  2013cited by this paper
• Trypanothione-based redox metabolism of trypanosomatids.

  2013cited by this paper
• Rational Selection of Anti‐Microbial Drug Targets: Unique or Conserved?

  2013cited by this paper
• Drug targets in trypanosomal and leishmanial pentose phosphate pathway.

  2013cited by this paper
• The Role of Glutathione Synthetase in Trypanothione Biosynthesis in Trypanosoma brucei

  2013cited by this paper
• Exploring the Trypanosoma brucei Hsp83 Potential as a Target for Structure Guided Drug Design

  2013cited by this paper
• Non-peptidic Cruzain Inhibitors with Trypanocidal Activity Discovered by Virtual Screening and In Vitro Assay

  2013cited by this paper
• Farnesyl pyrophosphate synthase: a key enzyme in isoprenoid biosynthetic pathway and potential molecular target for drug development.

  2013cited by this paper
• Ebsulfur Is a Benzisothiazolone Cytocidal Inhibitor Targeting the Trypanothione Reductase of Trypanosoma brucei *

  2013cited by this paper
• Features of protein–protein interactions that translate into potent inhibitors: topology, surface area and affinity

  2012cited by this paper
• The Molecular Dynamics of Trypanosoma brucei UDP-Galactose 4′-Epimerase: A Drug Target for African Sleeping Sickness

  2012cited by this paper
• Crystal structure of dihydroorotate dehydrogenase from Leishmania major.

  2012cited by this paper
• The trypanothione system and its implications in the therapy of trypanosomatid diseases.

  2012cited by this paper
• High Throughput Screening against the Peroxidase Cascade of African Trypanosomes Identifies Antiparasitic Compounds That Inactivate Tryparedoxin*

  2012cited by this paper
• Bisphosphonate metal complexes as selective inhibitors of Trypanosoma cruzi farnesyl diphosphate synthase.

  2012cited by this paper
• Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.

  2011cited by this paper
• Cruzain : the path from target validation to the clinic.

  2011cited by this paper
• The Crystal Structure of the Leishmania major Deoxyuridine Triphosphate Nucleotidohydrolase in Complex with Nucleotide Analogues, dUMP, and Deoxyuridine*

  2011cited by this paper
• Assessing helical protein interfaces for inhibitor design.

  2011cited by this paper
• A decade of targets and patented drugs for chemotherapy of Chagas disease.

  2011cited by this paper
• Differential expression of Trypanosoma cruzi I associated with clinical forms of Chagas disease: overexpression of oxidative stress proteins in acute patient isolate.

  2011cited by this paper
• A tryparedoxin-dependent peroxidase protects African trypanosomes from membrane damage.

  2011cited by this paper
• Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database

  2010cited by this paper
• PyRosetta: a script-based interface for implementing molecular modeling algorithms using Rosetta

  2010cited by this paper
• 16-bromoepiandrosterone, an activator of the mammalian immune system, inhibits glucose 6-phosphate dehydrogenase from Trypanosoma cruzi and is toxic to these parasites grown in culture.

  2010cited by this paper
• Can self‐inhibitory peptides be derived from the interfaces of globular protein–protein interactions?

  2010cited by this paper
• Structure of Trypanosoma brucei glutathione synthetase: Domain and loop alterations in the catalytic cycle of a highly conserved enzyme

  2010cited by this paper
• Computer-Aided Identification of Trypanosoma brucei Uridine Diphosphate Galactose 4′-Epimerase Inhibitors: Toward the Development of Novel Therapies for African Sleeping Sickness

  2010cited by this paper
• Homodimeric enzymes as drug targets.

  2010cited by this paper
• Trypanothione Reductase High-Throughput Screening Campaign Identifies Novel Classes of Inhibitors with Antiparasitic Activity

  2009cited by this paper
• One Scaffold, Three Binding Modes: Novel and Selective Pteridine Reductase 1 Inhibitors Derived from Fragment Hits Discovered by Virtual Screening

  2009cited by this paper
• Sterol Biosynthesis Pathway as Target for Anti-trypanosomatid Drugs

  2009cited by this paper
• Structure-Based Design of Pteridine Reductase Inhibitors Targeting African Sleeping Sickness and the Leishmaniases†

  2009cited by this paper
• Structures of Trypanosoma cruzi dihydroorotate dehydrogenase complexed with substrates and products: atomic resolution insights into mechanisms of dihydroorotate oxidation and fumarate reduction.

  2008cited by this paper
• The pentose phosphate pathway in Trypanosoma cruzi: a potential target for the chemotherapy of Chagas disease.

  2007cited by this paper
• Thermodynamic characterization of substrate and inhibitor binding to Trypanosoma brucei 6‐phosphogluconate dehydrogenase

  2007cited by this paper
• Perturbation of the Dimer Interface of Triosephosphate Isomerase and its Effect on Trypanosoma cruzi

  2007cited by this paper
• Comparative genomic analysis of three Leishmania species that cause diverse human disease

  2007cited by this paper
• Ribose 5-phosphate isomerase type B from Trypanosoma cruzi: kinetic properties and site-directed mutagenesis reveal information about the reaction mechanism.

  2007cited by this paper
• Spatial chemical conservation of hot spot interactions in protein-protein complexes

  2007cited by this paper
• Reaching for high-hanging fruit in drug discovery at protein–protein interfaces

  2007cited by this paper
• Identification of Novel Inhibitors of UDP-Glc 4′-Epimerase, a Validated Drug Target for African Sleeping Sickness

  2007cited by this paper
• Synthesis and Biological Evaluation of Phosphate Prodrugs of 4-Phospho-d -erythronohydroxamic Acid, an Inhibitor of 6-Phosphogluconate Dehydrogenase

  2007cited by this paper
• Identification of novel inhibitors of UDP-Glc 4'-epimerase, a validated drug target for african sleeping sickness.

  2006cited by this paper
• Structure and reactivity of Trypanosoma brucei pteridine reductase: inhibition by the archetypal antifolate methotrexate

  2006cited by this paper
• Deoxyuridine triphosphate nucleotidohydrolase as a potential antiparasitic drug target.

  2005cited by this paper
• Farnesyl diphosphate synthase; regulation of product specificity.

  2005cited by this paper
• Dithiol proteins as guardians of the intracellular redox milieu in parasites: old and new drug targets in trypanosomes and malaria-causing plasmodia.

  2005cited by this paper
• Structures of Leishmania major pteridine reductase complexes reveal the active site features important for ligand binding and to guide inhibitor design.

  2005cited by this paper
• Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: Implications for drug design

  2005cited by this paper
• Opportunities and Challenges in Antiparasitic Drug Discovery

  2005cited by this paper
• The 6-phosphogluconate dehydrogenase from Trypanosoma cruzi: the absence of two inter-subunit salt bridges as a reason for enzyme instability.

  2004cited by this paper
• High-resolution crystal structure of Trypanosoma brucei UDP-galactose 4'-epimerase: a potential target for structure-based development of novel trypanocides.

  2003cited by this paper
• Involvement of conserved asparagine and arginine residues from the N‐terminal region in the catalytic mechanism of rat liver and Trypanosoma cruzi tyrosine aminotransferases

  2003cited by this paper
• The Global Burden of Disease Study

  2003cited by this paper
• Structure of pteridine reductase (PTR1) from Leishmania tarentolae.

  2003cited by this paper
• Trypanosoma brucei UDP-galactose 4' epimerase

  2003cited by this paper
• Characterization of deoxyuridine 5′‐triphosphate nucleotidohydrolase from Trypanosoma cruzi 1

  2002cited by this paper
• A simple physical model for binding energy hot spots in protein–protein complexes

  2002cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• Dihydrooxonate is a substrate of dihydroorotate dehydrogenase (DHOD) providing evidence for involvement of cysteine and serine residues in base catalysis.

  2001cited by this paper
• Residue frequencies and pairing preferences at protein–protein interfaces

  2001cited by this paper
• Synthetic peptides as inactivators of multimeric enzymes: inhibition of Plasmodium falciparum triosephosphate isomerase by interface peptides

  2001cited by this paper
• Mutant PTR1 proteins from Leishmania tarentolae: comparative kinetic properties and active-site labeling.

  1999cited by this paper
• Anatomy of hot spots in protein interfaces.

  1998cited by this paper
• The Roles of Pteridine Reductase 1 and Dihydrofolate Reductase-Thymidylate Synthase in Pteridine Metabolism in the Protozoan Parasite Leishmania major*

  1997cited by this paper
• Studies of protein‐protein interfaces: A statistical analysis of the hydrophobic effect

  1997cited by this paper
• Denaturation and reactivation of dimeric human glutathione reductase--an assay for folding inhibitors.

  1997cited by this paper
• 6-Phosphogluconate dehydrogenase from Trypanosoma brucei. Kinetic analysis and inhibition by trypanocidal drugs.

  1996cited by this paper
• A hot spot of binding energy in a hormone-receptor interface

  1995cited by this paper
• Surface, subunit interfaces and interior of oligomeric proteins.

  1988cited by this paper
• Protein Structure Communications Structural Biology and Crystallization Communications Trypanosoma Brucei Udp-galactose-4 -epimerase in Ternary Complex with Nad + and the Substrate Analogue Udp-4-deoxy-4-fluoro-a-d-galactose

  year unknowncited by this paper

• Kinetoplastid diseases: insights into the mechanisms of drug action and resistance for novel drug discovery

  2025cites this paper
• Outwitting an old neglected nemesis: A review on leveraging integrated data-driven approaches to aid in unraveling of leishmanicides of therapeutic potential.

  2020cites this paper
• Concerted motion of structure and active site charge is required for tyrosine aminotransferase activity in Leishmania parasite.

  2020cites this paper
• Theoretical study of new LmDHODH and LmTXNPx complexes: structure-based relationships

  2020cites this paper
• Structure based peptide design, molecular dynamics and MM-PBSA studies for targeting C terminal dimerization of NFAT5 DNA binding domain.

  2020cites this paper